Financials in USD. Standardized financial statements.
A compact view of how WuXi Biologics (Cayman) Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $21.23B | $18.68B | $17.03B | $15.27B | $10.29B | $5.61B | $3.98B | $2.53B | $1.62B | $989.03M |
| Revenue Growth? | +13.7% | +9.6% | +11.6% | +48.4% | +83.3% | +40.9% | +57.2% | +56.6% | +63.7% | 0.0% |
| Cost of Revenue? | $11.47B | $11.02B | $10.21B | $8.54B | $5.46B | $3.08B | $2.32B | $1.52B | $958.27M | $599.92M |
| Gross Profit? | $9.76B | $7.65B | $6.83B | $6.72B | $4.83B | $2.53B | $1.66B | $1.02B | $660.56M | $389.11M |
| Gross Margin? | +46.0% | +41.0% | +40.1% | +44.0% | +46.9% | +45.1% | +41.6% | +40.2% | +40.8% | +39.3% |
| Operating Expenses? | $3.28B | $2.68B | $2.38B | $2.38B | $1.64B | $771.43M | $601.77M | $323.62M | $223.92M | $161.88M |
| Operating Income? | $6.47B | $4.97B | $4.45B | $4.34B | $3.19B | $1.50B | $1.11B | $876.43M | $348.64M | $201.54M |
| EBITDA? | $8.17B | $6.43B | $5.50B | $6.22B | $4.51B | $2.31B | $1.37B | $881.49M | $471.39M | $319.08M |
| Income Before Tax | $7.07B | $4.83B | $4.17B | $5.36B | $3.99B | $1.97B | $1.13B | $737.72M | $303.69M | $175.85M |
| Income Tax Expense | $1.48B | $889.03M | $603.18M | $807.87M | $484.54M | $273.07M | $116.30M | $107.26M | $51.06M | $34.75M |
| Net Income? | $4.78B | $3.36B | $3.40B | $4.42B | $3.39B | $1.69B | $1.01B | $630.59M | $252.63M | $141.10M |
| EPS? | $1.19 | $0.82 | $0.81 | $1.06 | $0.81 | $0.43 | $0.27 | $0.16 | $0.08 | $0.04 |
| Diluted EPS? | $1.12 | $0.78 | $0.77 | $1.01 | $0.77 | $0.40 | $0.25 | $0.16 | $0.07 | $0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality